AFRM enters its August 25 earnings print in an unusual configuration: short sellers have been cutting exposure at pace, analysts are racing to lift targets, and the lending market is as loose as it has been all year — yet the stock is still down 8% over the past month, sitting at $76.71.
The most striking development in positioning is the scale of short covering since mid-July. Short interest has dropped from roughly 19 million shares on July 13 to just under 15 million today — a decline of more than 21% in a month — pulling the SI level to 5.2% of the free float. That retreat coincided almost exactly with earnings-season momentum across fintech, and it has left the lending market notably relaxed. Borrow availability has expanded sharply, now running at 838% — meaning there are roughly eight shares available to borrow for every one already lent out, comfortably above the 52-week low of 504%. Cost to borrow is close to zero at 0.41%, barely moving week-to-week. The options market adds a nuance: the put/call ratio at 1.09 is actually slightly below its 20-day average of 1.12, suggesting options traders are not rushing to hedge into the print — the z-score of -0.85 puts this firmly in neutral territory. Taken together, positioning looks notably uncrowded rather than defensively loaded.
The Street has moved decisively in Affirm's favour over the past five weeks. BMO Capital raised its target to $86 from $78 this week while maintaining an Outperform rating. Earlier in July, Goldman Sachs lifted to $106, JPMorgan moved to $90, Wells Fargo to $96, and Barclays initiated at $97 — all carrying positive ratings. Most notably, Bernstein opened coverage on July 22 with an Outperform and a $100 target. TD Cowen sits at the top of the range with a $117 target. The consensus mean now sits at $91, implying roughly 19% upside to current levels. Bears point to execution risk in a competitive BNPL market, reliance on external funding, and the lingering question of whether partnerships with Amazon and Shopify can offset potential churn elsewhere. The valuation backdrop is less alarming than BNPL critics might expect: the stock trades at a P/E of 17.7x and an EV/EBITDA of 17.8x — both multiples have eased over the past month. Where the factor scores diverge sharply, however, is between analyst-driven momentum and fundamental earnings visibility: EPS momentum over 30 and 90 days ranks in the 96th–98th percentile, but EPS surprise ranks only in the 23rd percentile, and the forward EPS growth score sits in the 28th. The Street is optimistic; realized surprises have been more mixed.
Institutional flows are broadly constructive. Capital Research added 5.5 million shares as of July 31, bringing its stake to 14.2% of the company — by far the largest holder. FMR added 3.2 million shares over the same period. Founder Max Levchin holds 8.1% and has not changed his position. Insider activity is routine rather than signal-bearing: the COO, President, and Chief Legal Officer each received awards and sold small tranches on July 31 — all at significance scores of 1 and values well under $100,000 — the kind of programmatic compensation activity that carries no directional read.
The earnings history here is thin but consistent in one direction: the last four reported prints each produced a negative next-day move, ranging from roughly -1.4% to -2.4%. The five-day window after the most recent May 7 print recovered to +3%, suggesting initial selling was absorbed. With short interest already well reduced and the borrow market loose, any post-print pressure this time would face less mechanical covering to cushion it — and any upside surprise would find fewer shorts to squeeze.
With the August 25 print now two weeks away, the question worth tracking is whether the widening gap between analyst optimism and realized EPS surprise begins to narrow — or whether this quarter finally delivers the beat the Street has been pricing in for months.
See the live data behind this article on ORTEX.
Open AFRM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
